In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in ovarian cancer, uterine cancer, cervical cancer, multiple myeloma, and head and neck cancer.
Read about four studies presented at the 2023 ASCO Breakthrough meeting, covering new ways to use technology to improve cancer screening, as well as a study that showed exercise can help improve sexual health for people with prostate cancer.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in breast cancer, lymphoma, multiple myeloma, brain tumors, and von Hippel-Lindau syndrome.
Read research from the July 2023 session of the ASCO Plenary Series, which highlights a study evaluating a potential maintenance therapy option for people with advanced or recurrent TP53 wild-type endometrial cancer.
La Reunión Anual de la American Society of Clinical Oncology (Asociación Estadounidense de Oncología Clínica) se llevará a cabo del 2 al 6 de junio. Un estudio presentado hoy muestra que la eliminación de la radioterapia del plan de tratamiento para una forma agresiva de linfoma no afecta al riesgo de recurrencia o supervivencia general.
The ASCO Annual Meeting is being held June 2 to 6. A study presented today shows that removing radiation therapy from the treatment plan for an aggressive form of lymphoma does not impact the risk of recurrence or overall survival.
La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) se llevará a cabo del 2 al 6 de junio. Los aspectos destacados de la investigación del día incluyen el uso de trastuzumab deruxtecán para tratar tumores positivos para HER2 (receptor 2 del factor de crecimiento epidérmico humano) y el uso de terapia de células T con CAR (receptor de antígeno quimérico) para ralentizar o detener el mieloma múltiple.
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
La Reunión Anual de la American Society of Clinical Oncology (Asociación Estadounidense de Oncología Clínica) se llevará a cabo del 2 al 6 de junio. Hoy, se presentarán varios estudios destacados. Los temas incluyen la radioterapia en el cáncer de recto, osimertinib para el cáncer de pulmón, vorasidenib para el glioma de grado 2, nivolumab para el linfoma de Hodgkin y mirvetuximab soravtansina para el cáncer de ovario.
